124 related articles for article (PubMed ID: 8537279)
1. Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.
Chardon H; Farzaneh S; Labia R; Jarlier V; Nicolas MH; Paul G; Poyart C; Sirot D; Sirot J
J Antimicrob Chemother; 1995 Jul; 36(1):267-9. PubMed ID: 8537279
[No Abstract] [Full Text] [Related]
2. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989.
Seetulsingh PS; Hall LM; Livermore DM
J Antimicrob Chemother; 1991 Jun; 27(6):749-59. PubMed ID: 1938685
[TBL] [Abstract][Full Text] [Related]
3. Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993.
Espinasse F; Gheorghiu R; Poiata A; Labia R; Nicolas-Chanoine MH
J Antimicrob Chemother; 1997 Jan; 39(1):103-6. PubMed ID: 9044036
[TBL] [Abstract][Full Text] [Related]
4. Activity of amoxycillin/clavulanate against beta-lactamase-producing Escherichia coli and Klebsiella spp.
Roy C; Segura C; Torrellas A; Reig R; Teruel D; Hermida M
J Antimicrob Chemother; 1989 Nov; 24 Suppl B():41-7. PubMed ID: 2691485
[TBL] [Abstract][Full Text] [Related]
5. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
Stapleton P; Wu PJ; King A; Shannon K; French G; Phillips I
Antimicrob Agents Chemother; 1995 Nov; 39(11):2478-83. PubMed ID: 8585729
[TBL] [Abstract][Full Text] [Related]
6. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
Jacobs MR; Spangler SK; Appelbaum PC
J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
[TBL] [Abstract][Full Text] [Related]
7. First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains.
Lemozy J; Sirot D; Chanal C; Huc C; Labia R; Dabernat H; Sirot J
Antimicrob Agents Chemother; 1995 Nov; 39(11):2580-2. PubMed ID: 8585751
[TBL] [Abstract][Full Text] [Related]
8. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
[TBL] [Abstract][Full Text] [Related]
9. Effect of NCCLS, SFM, and DIN breakpoints upon the incidence of co-amoxiclav resistance in Escherichia coli.
Durodia J; Simpson I
J Antimicrob Chemother; 1995 Dec; 36(6):1105-6. PubMed ID: 8821615
[No Abstract] [Full Text] [Related]
10. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
Weber P; Plaisance JJ; Mancy C
J Antimicrob Chemother; 1994 Jul; 34(1):187-8. PubMed ID: 7961211
[No Abstract] [Full Text] [Related]
11. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.
Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
13. Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France.
Henquell C; Sirot D; Chanal C; De Champs C; Chatron P; Lafeuille B; Texier P; Sirot J; Cluzel R
J Antimicrob Chemother; 1994 Nov; 34(5):707-14. PubMed ID: 7706166
[TBL] [Abstract][Full Text] [Related]
14. Partial characterization of Nocardia farcinica beta-lactamases.
Steingrube VA; Wallace RJ; Brown BA; Zhang Y; Steele LC; Young G; Nash DR
Antimicrob Agents Chemother; 1993 Sep; 37(9):1850-5. PubMed ID: 8239595
[TBL] [Abstract][Full Text] [Related]
15. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
[TBL] [Abstract][Full Text] [Related]
16. [New antimicrobial agent series XXXVII: potassium clavulanate/Ticarcillin sodium].
Fujimori I
Jpn J Antibiot; 1991 Apr; 44(4):365-87. PubMed ID: 1880918
[No Abstract] [Full Text] [Related]
17. Molecular characterization of amoxicillin-clavulanate resistance in a clinical isolate of Escherichia coli.
Bellaaj A; Bollet C; Alfeddy N; Limam F; Belhadj C; Regli A; Chollet R; Belhadj O; Ben-Mahrez K
Microb Drug Resist; 2002; 8(4):267-72. PubMed ID: 12523623
[TBL] [Abstract][Full Text] [Related]
18. Beta-lactam resistance in Nocardia brasiliensis is mediated by beta-lactamase and reversed in the presence of clavulanic acid.
Wallace RJ; Nash DR; Johnson WK; Steele LC; Steingrube VA
J Infect Dis; 1987 Dec; 156(6):959-66. PubMed ID: 3500241
[TBL] [Abstract][Full Text] [Related]
19. Amoxycillin/clavulanate resistant Escherichia coli.
Williams H; King A; Shannon K; Phillips I
Lancet; 1988 Feb; 1(8580):304-5. PubMed ID: 2893121
[No Abstract] [Full Text] [Related]
20. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
Acar N; Diri MC; Türkyilmaz FR
Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
